The good news: China's Synovac company announces two phases of corona vaccine success

Beijing, Ta. 15 June 2020, Monday

The possibility of a second phase of corona virus transmission in China has created an atmosphere of fear around the world. Beijing-based pharmaceutical company Synovec Biotech has brought good news as markets in China are closing as new cases of corona continue to rise. The results of the human trial of the vaccine that the company is developing for the corona virus have come out safe and positive.

According to the company, this vaccine can boost our body's immune system in the fight against the corona virus. The vaccine is named "Coronavac" and the company says no major or dangerous effects were detected during its testing.

Increased immunity in 80 percent of people

A spokesman for Synovec Biotech said two doses of the vaccine were given to people involved in the test within 14 days but had no adverse effects on them. Ninety percent of the people involved in the trial had an increase in physical immunity.

Trial on 743 healthy people

A company spokesman said the Coronavek had been tried in China in two phases. It involved 743 healthy people between the ages of 18 and 59. 143 people were involved in the first phase of the trial and 600 in the second phase. The results of those who were vaccinated after an interval of 28 days are still pending.

Partnership with a Brazilian company

Synovac Biotech announced a partnership with the Buttan Institute later this month to conduct its third phase of testing in Brazil. In Brazil, a new type of pathogen has caused another wave of corona epidemics that has infected more than 77 million people so far.

However, measures such as lockdowns and social distance have helped keep transition rates low in many countries. Some of the world’s leading vaccine companies are trying to conduct a third phase test in active areas affected by corona to evaluate the effectiveness of their drugs.

Approved the development of vaccines

Brazilian authorities have approved the co-development of the vaccine by Oxford University and AstraZeneca plc so that the final phase can be tested there. While Cambridge Massachusetts-based Modern Inc. is ready to go into the third phase of testing in America.